Xunming Biotech has secured an additional Series B financing round totaling 100 million US dollars.

36Kr has learned that Xunming Biotech recently secured a Series B financing with a total amount of 100 million US dollars. The first tranche was exclusively invested by Granite Asia (formerly the Asian business of GGV Capital); the subsequent tranches were led by industrial investors, with Honghui Fund participating in the follow-on investment, and existing shareholders including Qiming Venture Partners, Matrix Partners China and New Alliance Capital making additional investments. Only more than 3 months have passed since the company disclosed its $35 million Series A+ financing.